Sanofi (SNYN) AI Stock Analysis

Sanofi

(BMV:SNYN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Growth and GuidanceThe upgraded 2026 outlook signals sustained commercial momentum across Sanofi’s portfolio rather than dependence on a single quarter. Low-teens sales growth and mid-teens business EPS growth should support reinvestment, strengthen operating leverage, and improve earnings durability over the next several quarters.

Negative Factors

Pipeline ProductivityA pipeline that trails peers and recent program discontinuations create a durable replenishment challenge for a research-driven company. Sanofi must improve productivity and external sourcing to replace aging products, increasing execution demands and uncertainty around future growth.

Sanofi (SNYN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 109.82B
Dividend Yield: 5.52%
Average Volume (3M): 251
Price to Earnings (P/E): 24.7
Beta (1Y): 0.12
Revenue Growth: 12.71%
EPS Growth: -37.01%
Country: Mexico
Employees: 76,493
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - General

Sanofi Business Overview & Revenue Model

Company Description

Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The com...

Sanofi Earnings Call Summary

Earnings Call Date:Oct 29, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Jan 27, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. Sanofi reported robust Q3 revenue, earnings, margin, Dupixent, new-launch, and rare-disease growth, upgraded 2026 guidance, and outlined significant strategic, R&D, AI, and external-innovation initiatives. The main challenges were the need to rebuild a pipeline that lags peers, discontinued development programs, vaccine phasing and supply constraints, upcoming portfolio-related sales reductions, Dupixent loss-of-exclusivity planning, and several areas of financial and regulatory uncertainty. The positive operating performance and breadth of stated growth initiatives significantly outweighed the disclosed challenges.

Positive Updates

Strong Third-Quarter Revenue Growth

Q3 total sales reached EUR 14.4 billion, up 14.3% versus last year. Underlying group sales growth, excluding items considered more one-off in nature, was estimated at around 12%.

Negative Updates

Pipeline Optimization Included Major Program Discontinuations

Sanofi decided not to pursue global regulatory submissions for amlitelimab in atopic dermatitis and discontinued itepekimab development in COPD and chronic rhinosinusitis following benefit-risk reviews and consideration of available data and the competitive landscape.

Company Guidance

Sanofi upgraded 2026 guidance, expecting sales to grow at a low teens percentage, which usually means a range of 13%-15%, and business EPS to grow at a mid-teen percentage, which usually means between 15% and 17%; vaccine sales are expected to be down by a low single-digit percentage for the full year, while capital gains are expected to be around EUR 250 million and the Regeneron development balance ending creates a BOI headwind of about EUR 500 million in H2 2026, evenly distributed between Q3 and Q4. For 2027, Sanofi is not providing formal guidance, but expects pricing to return to a slightly negative pricing contribution to global sales growth, legacy-portfolio transactions to reduce sales by around EUR 1.3 billion, and BOI to increase in absolute value and BOI margin despite the H1 2027 impact of the end of the R&D reimbursement; cost base growth is expected at a lower level than sales. Sanofi expects Dupixent revenue of EUR 25 billion by 2030 and total group revenue to be impacted moderately by Dupixent's LOE, with a priority on preserving earnings and cash flow.

Sanofi Risk Analysis

Sanofi disclosed 29 risk factors in its most recent earnings report. Sanofi reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks

1.Failure to comply with data ethics and privacy regulations could adversely affect our business and reputationQ4, 2023

2.Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operationsQ4, 2023

3.A failure in our crisis and business continuity management processes in case of unpredictable events could have negative consequences for our business, operations and reputationQ4, 2023

Sanofi Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:SNYN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NVO	75Outperform	$176.53B	10.30	59.09%	4.44%	13.21%	12.68%
PFE	74Outperform	$173.95B	40.52	4.89%	5.61%	-0.21%	-59.71%
NVS	72Outperform	$298.74B	30.87	24.24%	2.93%	1.64%	-28.72%
JNJ	70Outperform	$657.68B	41.02	19.55%	1.95%	7.81%	-35.95%
GSK	67Neutral	$99.66B	16.89	24.64%	3.70%	6.93%	-18.14%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:SNYN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:SNYN	Sanofi SA	808.08	-93.80	-10.40%
GSK	GlaxoSmithKline	49.13	3.89	8.60%
JNJ	Johnson & Johnson	270.56	87.82	48.06%
NVS	Novartis AG	161.52	38.91	31.74%
NVO	Novo Nordisk	40.45	-6.21	-13.31%
PFE	Pfizer Inc	30.67	7.96	35.07%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Sanofi AI Stock Analysis